Ultragenyx Pharmaceutical Inc.
RARE
$29.78
$0.260.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.24% | 27.99% | 29.42% | 42.27% | 35.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.24% | 27.99% | 29.42% | 42.27% | 35.75% |
| Cost of Revenue | 2.71% | -0.81% | 8.21% | 91.33% | 4.53% |
| Gross Profit | 40.59% | 36.75% | -3.15% | 36.07% | 46.27% |
| SG&A Expenses | 7.50% | 12.33% | 7.37% | 7.25% | -0.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.18% | 2.94% | 15.12% | 11.65% | 2.78% |
| Operating Income | 7.28% | 13.55% | -0.19% | 9.04% | 21.35% |
| Income Before Tax | 12.80% | 12.02% | -5.13% | 16.22% | 17.82% |
| Income Tax Expenses | 10.37% | 187.91% | 99.49% | -53.38% | 17.21% |
| Earnings from Continuing Operations | 12.65% | 11.49% | -8.28% | 16.37% | 17.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.65% | 11.49% | -8.28% | 16.37% | 17.66% |
| EBIT | 7.28% | 13.55% | -0.19% | 9.04% | 21.35% |
| EBITDA | 7.66% | 14.41% | 0.56% | 10.64% | 24.61% |
| EPS Basic | 23.19% | 22.52% | 8.20% | 37.24% | 32.58% |
| Normalized Basic EPS | 20.92% | 24.73% | 13.19% | 36.24% | 34.87% |
| EPS Diluted | 23.19% | 22.52% | 8.20% | 37.24% | 32.58% |
| Normalized Diluted EPS | 20.92% | 24.73% | 13.19% | 36.24% | 34.87% |
| Average Basic Shares Outstanding | 13.72% | 14.24% | 17.95% | 33.25% | 22.12% |
| Average Diluted Shares Outstanding | 13.72% | 14.24% | 17.95% | 33.25% | 22.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |